Dutch Antibody-Drug Conjugates Licensed to Chinese Pharma for up to €111M

Shanghai Miracogen will pay up to €111M ($125M) to develop cancer treatments based on antibody-drug conjugate technology from the Dutch company Synaffix.

Synaffix develops antibody-drug conjugates, commonly known as ADCs, which are antibodies with toxic chemotherapy drugs attached. The carrier antibody guides the drug to cancer cells, only killing cells in a small area around the tumor and sparing healthy tissue from the toxic drug’s effects.

Generally speaking, this translates into a therapeutic that is more effective at eradicating cancer cells and also much better tolerated by patients,” Peter van de Sande, the CEO of Synaffix, told me.

ADVERTISEMENT

Shanghai Miracogen will pay up to €111M ($125M) for non-exclusive rights to Synaffix’s technology. The full payment is subject to Shanghai Miracogen reaching certain undisclosed milestones. The Chinese pharma company will develop and commercialize a candidate drug that the partners developed previously, and Synaffix will manufacture the technology for clinical testing. The partners declined to disclose the cancers that they are targeting in this partnership.

Making ADCs is a complex task, and only four have been approved by the FDA so far. Synaffix believes that its technology can develop them faster than other ADC companies by using fewer steps in the antibody production process.

The Chinese biotech industry is gaining interest in collaborating with foreign companies for biotech innovation, such as Genecast Biotechnology partnering with US company Cancer Genetics to commercialize a diagnostic cancer test in China in 2018. Broad reforms in the drug regulation pathways in China have opened up the industry to more foreign innovation, and allowed a lot of growth in these areas. Synaffix’s latest deal likely isn’t the last European and Chinese biotech deal in the works, so watch this space. 


Images from Shutterstock

Let's Continue The Conversation

Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.